Skip to content
Screener

Anika Therapeutics ANIK Business Segments — Interest Income Expense Nonoperating Net

Similar metrics at other companies

Dollar General logo
DGSingle Reportable — Interest Income Expense Nonoperating Net
-$47.24M+26.9%
Napco Security Technologies logo
NSSCSingle Reportable — Interest Income Expense Nonoperating Net
$986K+14.4%
Edgewise Therapeutics, Inc. logo
EWTXSingle Reportable — Interest Income Expense Nonoperating Net
$5.1M-1.1%
Norwegian Cruise Line Holdings Ltd. logo
NCLHSingle Reportable — Interest Income Expense Nonoperating Net
-$165.99M+23.8%
Cracker Barrel Old Country Store logo
CBRLSingle Reportable — Interest Income Expense Nonoperating Net
-$3.67M+26.4%
Onto Innovation logo
ONTOSingle Reportable — Interest Income Expense Nonoperating Net
$8.74M+4.4%

Other financials

Income statement

See full
Revenue$32.6M+15.6%
Net income$3.3M+183%

Balance sheet

See full
Cash & equivalents$38.4M-27.8%
Total debt$25.3M+1.0%
Total equity$137.3M-7.0%
Total assets$183.5M-2.2%

Cash flow

See full
Operating cash flow-$684.0K-262%
CapEx$1.4M-1.2%
Free cash flow-$2.1M-28.8%

Valuation

See full
Market cap$256.82M+116%
Enterprise value$243.66M+168%
P/S2.1×+0.9×

Profitability

See full
Net margin-3.4%-1.6pp
FCF margin0.5%

Returns & leverage

See full
Return on equity-2.9%-1.4pp
Debt / equity0.2×0.0×
Current ratio4.5×-1.7×

Where this comes from

Reported directly by Anika Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.

The source filing: Anika Therapeutics’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:09 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001171843-26-005012
Line itemFor the Three Months Ended June 30, 2026For the Three Months Ended June 30, 2025For the Six Months Ended June 30, 2026For the Six Months Ended June 30, 2025
Selling, general & administrative10,94912,23028,72125,136
Total operating expenses18,29018,54342,77537,508
Income (loss) from operations2,954(4,180)(2,534)(8,464)
Interest and other income, net4262141,093629
Income (loss) before income taxes3,380(3,966)(1,441)(7,835)
Provision for income taxes71681306770
Income (loss) from continuing operations3,309(4,647)(1,747)(8,605)
Income (loss) from discontinued operations, net of tax-677-(238)

ITEM 1. FINANCIAL STATEMENTS[ Item 1. Condensed Consolidated Financial Statements (unaudited): ](#)

FAQ

What is Anika Therapeutics's business segments — interest income expense nonoperating net?
Anika Therapeutics (ANIK) reported business segments — interest income expense nonoperating net of $426K in Q2 2026.
What does business segments — interest income expense nonoperating net mean?
This reflects the net balance of interest income earned on cash reserves and interest expenses incurred on debt obligations. It highlights the impact of the company's capital structure and treasury management on its overall financial results.

Ask your AI about Anika Therapeutics's business segments — interest income expense nonoperating net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude